Exploring the use of conformationally locked aminoglycosides as a new strategy to overcome bacterial resistance

Journal of the American Chemical Society

Volumn 128, Issue 1, 2006, Pages 100-116

  Bastida, Agatha ^a   Hidalgo, Ana ^a   Chiara, Jose Luis ^a   Torrado, Mario ^a   Corzana, Francisco ^a   Pérez Cañadillas, Jose Manuel ^b   Groves, Patrick ^c   Garcia Junceda, Eduardo ^a   Gonzalez, Carlos ^b   Jimenez Barbero, Jesús ^c   Asensio, Juan Luis ^a  

^a INSTITUTO DE QUÍMICA ORGÁNICA GENERAL   (Spain)

^b INSTITUTO DE QUÍMICA FÍSICA ROCASOLANO   (Spain)

^c CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; BACTERIA; BIOCHEMISTRY; OLIGOMERS;

BACTERIAL RESISTANCE; ENZYMATIC INACTIVATION; ENZYMATIC MODIFICATION; OLIGOSACCHARIDES;

CONFORMATIONS;

AMINOGLYCOSIDE ANTIBIOTIC AGENT; FRAMYCETIN; OLIGOSACCHARIDE; RIBOSOME RNA;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; DRUG CONFORMATION; DRUG DESIGN; DRUG INACTIVATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME MODIFICATION; NONHUMAN; RNA BINDING; STRUCTURE ACTIVITY RELATION;

ACETYLTRANSFERASES; AMINOGLYCOSIDES; BACTERIAL PROTEINS; CARBOHYDRATE CONFORMATION; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; FRAMYCETIN; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; NUCLEOTIDYLTRANSFERASES; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RIBOSE; RNA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 30844466867     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja0543144     Document Type: Article

References (54)

1. Walter, F.; Vicens, Q.; Westhof, E. Curr. Opin. Chem. Biol. 1999, 3, 694-704.
2. Hermann, T. Angew. Chem., Int. Ed. 2000, 39, 1890-1905.
3. Schroeder, R.; Waldsich, C.; Wank, H. EMBO J. 2000, 19, 1, 1-9.
4. Sucheck, J. S.; Wong, C. H. Curr. Opin. Chem. Biol. 2000, 4, 678-686.
5. Carter, A. P.; Clemons, W. M.; Brodersen, D. E.; Morgan-Warren, R. J.; Wirnberly, B. T.; Ramakrishnan, V. Nature 2000, 407, 340-348.
6. (a) Vicens, Q.; Westhof, E. Structure 2001, 9, 647-658.
7. (b) Vicens, Q.; Westhof, E. Chem. Biol. 2002, 9, 747-755.
8. (a) Yoshizawa, S.; Fourmy, D.; Puglisi. J. D. EMBO J. 1998, 17, 22, 6437-6448.
9. (b) Fourmy, D.; Recht, M. I.; Blanchard, A. C.; Puglisi, J. D. Science 1996, 274, 1367-1371.
10. (c) Lynch, S. R.; Gonzalez, R. L., Jr.; Puglisi, J. D. Structure 2003, 11, 43-53.
11. Magnet, S.; Blanchard, J. Chem. Rev. 2005, 105, 477-497.
12. Smith, C. A.; Baker, E. N. Curr. Drug Targets 2002, 2, 143-160.
13. (a) Kondo, S.; Iinuma, K.; Yumamoto, H.; Mneda, K.; Umezawa, H. J. Antibiol. 1975, 26, 412-417,
14. (b) Kondo, S.; Hotta, K. J. Infect. Chemother. 1990, 5, 1.
15. Inoue, M.; Nonoyama, M.; Okamoto, R.; Ida, T. Drugs Exp. Clin. Res. 1994, 20, 233-239.
16. Fujimum, S.; Tokue, Y.; Takahashi, H.; Nukiwu, T.; Hisamichi, K.; Mikami, T.; Watanabe, A. J.; Antimicrob. Chemother. 1998, 41, 495-499.
17. (a) Roestamadji, J.; Graspas, I.; Mobashery, S. J. Am Chem. Soc. 1995, 117, 110060-11069.
18. (b) McKay, G. A.; Roestamadji, J.; Mobashery, S.; Wright, G. D. Antimicrob. Agents Chemother. 1996, 40, 2648.
19. (c) Haddad, J.; Vakulenku, S.; Mobashery, S. J. Am. Chem. Soc. 1999, 121, 11922-11923.
20. (d) Grapsas, I.; Lerner, S. A.; Mobashery, S. Arch. Pharm. 2001, 334, 295.
21. Vicens, Q.; Westhof, E. Biopolymers 2003, 70, 42-57.
22. Pedersen, L. C.; Benning, M. M.; Holden, H. M. Biochemistry 1995, 34, 13305-13311.
23. Asensio, J. L.; Hidalgo, A.; Cuesta, I.; González, C.; Cañada, J.; Vicent, C.; Chiara, J. L.; Cuevas, G.; Jiménez-Barbero, J. Chem. Eur. J. 2002, 8, 22, 5228-5240.
24. Vetting, M. W.; Hegde, S. S.; Javid-Majd, F.; Blanchard, J. S.; Roderick, S. L. Nat. Struct. Biol. 2002, 9, 653-658.
25. Vetting, M. W.; Magnet, S.; Nieves, E.; Roderick, S. L.; Blanchard, J. S. Chem. Biol. 2004, 11, 565-573.
26. Fong, D. H.; Berghuis, A. M. EMBO J. 2002, 27, 2323-2331.
27. A key example of how the enzymatic activity can be modulated by small conformational preferences of the substrates was reported recently: Galan, M. C.; Venot, A. P.; Boons, G. J. Biochemistry 2003, 42, 8522-8529.
28. A preliminary communication on some of the aspects described above has been recently published: Asensio, J. L.; Hidalgo, A.; Bastida, A.; Torrado, M.; Corzana, F.; García-Junceda, E.; Cañada, J.; Chiara, J. L.; Jiménez-Barbero, J. J. Am. Chem. Soc. 2005, 127, 8278-8279.
29. Kumar, V.; Remers, W. A. J. Org. Chem. 1981, 46, 4298-4300.
30. Michael, K.; Wang, H.; Tor, Y. Bioorg. Med. Chem. 1999, 7, 1361-1372.
31. Mori, K.; Tominaga, M.; Takigawa, T.; Matsui, M. Synthesis 1973, 790-791.
32. Pearlman, D. A. J. Biomol. NMR 1994, 4, 1-16.
33. Pearlman, D. A.; Case, D. A.; Caldwell, J. W.; Ross, W. S.; Cheatham, T. E.; DeBolt, S.; Ferguson, D.; Siebal, G.; Kollman, P. Comput. Phys. Commun. 1995, 91, 1-41.
34. Altona, C.; Sundaralingham, M. J. Am. Chem. Soc. 1972, 94, 8205-8208.
35. Kaul, M.; Barbieri, C. M.; Pilch, D. S. J. Am. Chem. Soc. 2004, 126, 3447-3453.
36. Shandrick, S.; Zhao, Q.; Han, Q.; Ayida, B. K.; Takahashi, M.; Winters, G, C.; Simonsen, K. B.; Vourloumis, D.; Hermann, T. Angew. Chem., Int. Ed. 2004, 43, 3177-3182.
37. (a) Wang, Y.; Hamasaki, K.; Rando, R. R. Biochemistry 1997, 36, 768-779,
38. (b) Ryu, D. H.; Litovchick, A.; Rando, R. R. Biochemistry 2002, 4l, 10499-10509.
39. (c) Fourmy, D.; Recht, M. I.; Puglisi, J. D. J. Mol. Biol. 1998, 277, 347-362.
40. While this manuscript was in preparation, Tor and co-workers reported the interaction of both the locked derivative 2 and the corresponding paromomycin analogue with the same labeled A-site RNA fragment. Athough the buffer conditions employed for the flourescence measurements differ from ours, the reported decrease in affinity for the locked derivatives is 22-14-fold with respect to the parent aminoglycosides, in agreement with our results; Blount, K. F.; Zhao, F.; Flermann, T.; Tor, Y. J. Am. Chem. Soc. 2005, 127 (27), 9818-9829.
41. The 3D structure of derivative 2 in complex with the A-site, reported by Hermann and col while this manuscript was under revision, shows that rings III and IV present a slightly diffeerent orientation in the RNA major grouve from that observed for natural Neomycin-B. As a result, the number of ligand-RNA contacts established by these two units is reduced. Zhao, F.; Zhao, Q.; Blount, K. F.; Han, Q.; Tor, Y.; Hermann, T. Angew. Chem., Int. Ed. 2005, 44, 5329-5334.
42. (a) Williams, D. H.; Searle, M. S.; Mackay, J. P.; Gerhard, U.; Maplestone, R. A. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 1172-1178.
43. (b) Calderone, C. T.; Williams, D. H. J. Am. Chem. Soc. 2001, 123, 6262-6267.
44. (a) Choi, Y.; Moon, H. R.; Yoshimura, Y.; Marquez., V. E. Nucleoside Nucleotide Nucleic Acids 2003, 22, 547-557.
45. (b) Kim, H. S.; Ohno, M.; Xu, B.; Kim, H. O.; Choi, Y.; Ji, X, D.; Maddileti, S.; Marquez, V. E.; Harden, T. K.; Jacobson, K. A, J. Med. Chem. 2003, 46, 4974-4987.
46. Navarre, N.; Amiot, N.; van Oijen, A. H.; Imberty, A.; Poveda, A.; Jiménez-Barbero, J.; Nulley, M. A.; Boons, G. J. Chem. Eur. J. 1999, 5, 2281-2294.
47. Bundle, D. R.; Alibés, R.; Nilar, S.; Ouer, A.; Warwas, M.; Zhang, P. J. Am. Chem. Soc. 1998, 120, 5317-5318.
48. Francois, B.; Szychowski, J.; Adhikari, S. S.; Pachamuthu, K.; Swayze, E. E.; Griffey, R. H.; Migawa, M. T.; Westhof, E.; Hanessian, S. Angew. Chem., Int. Ed. 2004, 43, 6735-6738.
49. Pople, J. A. et al. Gaussian-94; Inc.: Pittsburgh, PA, 1995.
50. Cornell, W. D.; Cieplack, P. C.; Bayly, I.; Goald, I. R.; Merz, K.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. J. Am. Chem. Soc. 1905, 117, 5179-5197.
51. Woods, R. J.; Dwek, R. A.; Edge, C. J.; Fraser-Reid, D. J. Phys. Chem. 1995, 99, 3832-3839.
52. Haselhorst, T.; Weimar, T.; Peters, T. J. Am. Chem. Soc. 2001, 123, 10705-10714.
53. Hegde, S. S.; Javid-Majd, F.; Blanchard, J. S. J. Biol. Chem. 2001, 276, 49, 45876-45881.
54. Waterworth, P. M. In Laboratory Methods in Antimicrobial Chemotherapy; Garrod, L., Ed.; Churchill Livingstone Press: Edinburgh, 1978; pp 31-40.